The co-existence of diabetes and subclinical atherosclerosis in rural central Appalachia: Do residential characteristics matter?


Journal

Journal of diabetes and its complications
ISSN: 1873-460X
Titre abrégé: J Diabetes Complications
Pays: United States
ID NLM: 9204583

Informations de publication

Date de publication:
04 2021
Historique:
received: 13 12 2020
accepted: 02 01 2021
pubmed: 21 1 2021
medline: 31 12 2021
entrez: 20 1 2021
Statut: ppublish

Résumé

Aim Disparities exist in cardiovascular diseases (CVD) and diabetes in the United States (U.S.) with Central Appalachia having disproportionate burden. This study examined prevalence and correlates of CVD risk-factors among patients with diabetes/subclinical atherosclerosis in Central Appalachia. During 2012-2016, 3000 patients from Central Appalachia were screened for subclinical atherosclerosis, using coronary artery calcium (CAC) scores; 419 participants had diabetes. Patients were categorized into four groups, with emphasis on those having subclinical atherosclerosis, CAC score ≥ 1. Descriptive statistics and multilevel multinomial logistic regression were conducted to identify CVD risk and spatial factors associated with co-existence of diabetes and subclinical atherosclerosis. Among participants, prevalence of CVD risk-factors ranged from 11.7% for current smokers to 69.2% for those with CVD family history. Average BMI was 29.8. Compared to patients with diabetes only, age [RR = 1.07; p ≤ 0.0001], being male [RR = 5.33; p ≤ 0.0001], having hypertension [RR = 2.37; p ≤ 0.05] and being a former smoker were associated with increased likelihood of having diabetes/subclinical atherosclerosis. At the zip-code level, unemployment rate [RR = 1.37; p ≤ 0.05] was significantly associated with having diabetes/subclinical atherosclerosis. Consistent with clinical guidelines, study results suggest the need to integrate CAC screening into primary care diabetes programs while addressing spatial issues that predispose patients to have diabetes/subclinical atherosclerosis.

Identifiants

pubmed: 33468398
pii: S1056-8727(21)00005-2
doi: 10.1016/j.jdiacomp.2021.107851
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107851

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Matthew Budoff has funding from General Electric. All the other authors declares that there is no conflict of interest.

Auteurs

Hadii M Mamudu (HM)

College of Public Health, East Tennessee State University, Johnson City, TN 37614, USA. Electronic address: mamudu@etsu.edu.

Antwan Jones (A)

Department of Sociology and Department of Epidemiology & Biostatistics, The George Washington University, Washington, DC 20052, USA.

Timir K Paul (TK)

John H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.

Fenose Osedeme (F)

College of Public Health, East Tennessee State University, Johnson City, TN 37614, USA.

David Stewart (D)

Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN 37614, USA.

Arsham Alamian (A)

College of Public Health, East Tennessee State University, Johnson City, TN 37614, USA.

Liang Wang (L)

College of Public Health, East Tennessee State University, Johnson City, TN 37614, USA.

Sylvester Orimaye (S)

College of Public Health, East Tennessee State University, Johnson City, TN 37614, USA.

James Bledsoe (J)

College of Public Health, East Tennessee State University, Johnson City, TN 37614, USA.

Amy Poole (A)

College of Public Health, East Tennessee State University, Johnson City, TN 37614, USA.

Gerald Blackwell (G)

Ballad Health, Kingsport, TN 37660, USA.

Mathew Budoff (M)

Los Angeles Biomedical Research Institute, University of California in Los Angeles, Los Angeles, California 90502, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH